What drugs are used to treat patients with heart failure?

1. Olsen SL, et al., Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol, 1995. 25(6): p. 1225–31. [PubMed] [Google Scholar]

2. Bristow MR, et al., Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation, 1996. 94(11): p. 2807–16. [PubMed] [Google Scholar]

3. Yoshikawa T, et al., Cardiac adrenergic receptor effects of carvedilol. Eur Heart J, 1996. 17 Suppl B: p. 8–16. [PubMed] [Google Scholar]

4. Bristow MR and Gilbert EM, Improvement in cardiac myocyte function by biological effects of medical therapy: a new concept in the treatment of heart failure. Eur Heart J, 1995. 16 Suppl F: p. 20–31. [PubMed] [Google Scholar]

5. Packer M, et al., Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation, 1999. 100(23): p. 2312–8. [PubMed] [Google Scholar]

6. Konstam MA, et al., Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet, 2009. 374(9704): p. 1840–8. [PubMed] [Google Scholar]

7. Packer M, et al., Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med, 2001. 344(22): p. 1651–8. [PubMed] [Google Scholar]

8. McMurray JJ, et al., Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med, 2014. 371(11): p. 993–1004. [PubMed] [Google Scholar]

9. Heywood JT, et al., Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF. Circ Heart Fail, 2010. 3(5): p. 596–605. [PubMed] [Google Scholar]

10. Investigators S, et al., Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med, 1992. 327(10): p. 685–91. [PubMed] [Google Scholar]

11. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med, 1991. 325(5): p. 293–302. [PubMed] [Google Scholar]

12. Hjalmarson A, et al., Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA, 2000. 283(10): p. 1295–302. [PubMed] [Google Scholar]

13. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet, 1999. 353(9169): p. 2001–7. [PubMed] [Google Scholar]

14. Pitt B, et al., The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med, 1999. 341(10): p. 709–17. [PubMed] [Google Scholar]

15. Juurlink DN, et al., Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med, 2004. 351(6): p. 543–51. [PubMed] [Google Scholar]

16. Taylor AL, et al., Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med, 2004. 351(20): p. 2049–57. [PubMed] [Google Scholar]

17. Vardeny O, et al., Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail, 2016. 18(10): p. 1228–1234. [PMC free article] [PubMed] [Google Scholar]

18. Osterziel KJ, Carvedilol in heart failure: the MOCHA trial. Circulation, 1997. 96(8): p. 2742; author reply 2743–4. [PubMed] [Google Scholar]

19. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol, 1996. 78(8): p. 902–7. [PubMed] [Google Scholar]

20. Desai AS, et al., Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol, 2017. 2(1): p. 79–85. [PubMed] [Google Scholar]

21. Cole RT, et al., Hydralazine and isosorbide dinitrate in heart failure: historical perspective, mechanisms, and future directions. Circulation, 2011. 123(21): p. 2414–22. [PubMed] [Google Scholar]

22. Majumdar SR, et al., Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. Clin Ther, 2004. 26(5): p. 694–703. [PubMed] [Google Scholar]

23. Fiuzat M, et al., Heart Rate or Beta-Blocker Dose? Association With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction: Results From the HF-ACTION Trial. JACC Heart Fail, 2016. 4(2): p. 109–15. [PubMed] [Google Scholar]

24. O’Connor CM, et al., Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA, 2009. 301(14): p. 1439–50. [PMC free article] [PubMed] [Google Scholar]

25. Vardeny O, et al., Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail, 2016. [PMC free article] [PubMed] [Google Scholar]

26. Yancy CW, et al., 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation, 2017. [PubMed] [Google Scholar]

27. Hunt SA, et al., ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation, 2005. 112(12): p. e154–235. [PubMed] [Google Scholar]

28. Gheorghiade M, et al., Medication dosing in outpatients with heart failure after implementation of a practice-based performance improvement intervention: findings from IMPROVE HF. Congest Heart Fail, 2012. 18(1): p. 9–17. [PubMed] [Google Scholar]

29. Cohn JN, Tognoni G, and Valsartan I Heart Failure Trial, A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med, 2001. 345(23): p. 1667–75. [PubMed] [Google Scholar]

30. Krum H, et al., Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study. JAMA, 2003. 289(6): p. 712–8. [PubMed] [Google Scholar]

31. Wikstrand J, et al., How should subgroup analyses affect clinical practice? Insights from the Metoprolol Succinate Controlled-Release/Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Card Electrophysiol Rev, 2003. 7(3): p. 264–75. [PubMed] [Google Scholar]

32. Komajda M, et al., Physicians’ adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. Eur J Heart Fail, 2016. 18(5): p. 514–22. [PubMed] [Google Scholar]

33. Yancy CW, et al., Adherence to guideline-recommended adjunctive heart failure therapies among outpatient cardiology practices (findings from IMPROVE HF). Am J Cardiol, 2010. 105(2): p. 255–60. [PubMed] [Google Scholar]

34. Golwala HB, et al., Use of hydralazine-isosorbide dinitrate combination in African American and other race/ethnic group patients with heart failure and reduced left ventricular ejection fraction. J Am Heart Assoc, 2013. 2(4): p. e000214. [PMC free article] [PubMed] [Google Scholar]

35. Sessa M, et al., Relationship between heart failure, concurrent chronic obstructive pulmonary disease and beta-blocker use: a Danish nationwide cohort study. Eur J Heart Fail, 2017. [PubMed] [Google Scholar]

36. Canepa M, et al., Characteristics, treatments and 1-year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long-Term Registry. Eur J Heart Fail, 2017. [PubMed] [Google Scholar]

37. Franciosa JA, et al., Beta-blocker therapy for heart failure outside the clinical trial setting: findings of a community-based registry. Am Heart J, 2004. 148(4): p. 718–26. [PubMed] [Google Scholar]

38. Ghali JK, et al., Consistency of the beneficial effect of metoprolol succinate extended release across a wide range dose of angiotensin-converting enzyme inhibitors and digitalis. J Card Fail, 2004. 10(6): p. 452–9. [PubMed] [Google Scholar]

39. Krum H, et al., Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur J Heart Fail, 2004. 6(7): p. 937–45. [PubMed] [Google Scholar]

40. Januzzi JL Jr., et al., Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med, 2006. 166(3): p. 315–20. [PubMed] [Google Scholar]

41. Fonarow GC, et al., Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol, 2007. 49(19): p. 1943–50. [PubMed] [Google Scholar]

42. Hartmann F, et al., Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation, 2004. 110(13): p. 1780–6. [PubMed] [Google Scholar]

43. Bettencourt P, et al., N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation, 2004. 110(15): p. 2168–74. [PubMed] [Google Scholar]

44. Stienen S, et al., NT-proBNP-Guided Therapy in Acute Decompensated Heart Failure: The PRIMA II Randomized Controlled Trial. Circulation, 2017. [PubMed] [Google Scholar]

45. Felker GM, et al., Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA, 2017. 318(8): p. 713–720. [PMC free article] [PubMed] [Google Scholar]

46. Frantz RP, et al., Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure. Am Heart J, 2005. 149(3): p. 541–7. [PubMed] [Google Scholar]

47. Masson S, et al., Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol, 2008. 52(12): p. 997–1003. [PubMed] [Google Scholar]

48. Tsutamoto T, et al., Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol, 2001. 37(5): p. 1228–33. [PubMed] [Google Scholar]

49. Zile MR, et al., Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. J Am Coll Cardiol, 2016. 68(22): p. 2425–2436. [PubMed] [Google Scholar]

50. Ansari M, et al., Improving guideline adherence: a randomized trial evaluating strategies to increase beta-blocker use in heart failure. Circulation, 2003. 107(22): p. 2799–804. [PubMed] [Google Scholar]

51. Vaduganathan M, et al., Integrating electronic health records into the study of heart failure: promises and pitfalls. Eur J Heart Fail, 2017. [PubMed] [Google Scholar]

52. Butler J, et al., Tolerability to beta-blocker therapy among heart failure patients in clinical practice. J Card Fail, 2003. 9(3): p. 203–9. [PubMed] [Google Scholar]

53. Bhatt AS, et al., Achieving a Maximally Tolerated beta-Blocker Dose in Heart Failure Patients: Is There Room for Improvement? J Am Coll Cardiol, 2017. 69(20): p. 2542–2550. [PubMed] [Google Scholar]

54. Maeder MT, et al., Incidence, clinical predictors, and prognostic impact of worsening renal function in elderly patients with chronic heart failure on intensive medical therapy. Am Heart J, 2012. 163(3): p. 407–14, 414 e1. [PubMed] [Google Scholar]

55. Vardeny O, et al., Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail, 2014. 7(4): p. 573–9. [PubMed] [Google Scholar]

56. Triposkiadis F, et al., The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol, 2009. 54(19): p. 1747–62. [PubMed] [Google Scholar]

57. Braunwald E, Heart failure: pathophysiology and treatment. Am Heart J, 1981. 102(3 Pt 2): p. 486–90. [PubMed] [Google Scholar]

58. Teerlink JR, Ivabradine in heart failure--no paradigm SHIFT...yet. Lancet, 2010. 376(9744): p. 847–9. [PubMed] [Google Scholar]

59. Willenheimer R, et al., Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation, 2005. 112(16): p. 2426–35. [PubMed] [Google Scholar]

60. Sliwa K, et al., Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure. J Am Coll Cardiol, 2004. 44(9): p. 1825–30. [PubMed] [Google Scholar]

61. Funck-Brentano C, et al., Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial. Eur J Heart Fail, 2011. 13(7): p. 765–72. [PubMed] [Google Scholar]

62. Yancy CW, et al., 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol, 2018. 71(2): p. 201–230. [PubMed] [Google Scholar]

63. Butler J, et al., Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction. Circ Heart Fail, 2016. 9(11). [PubMed] [Google Scholar]

64. Cohn JN, et al., Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med, 1986. 314(24): p. 1547–52. [PubMed] [Google Scholar]

65. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med, 1987. 316(23): p. 1429–35. [PubMed] [Google Scholar]

66. Packer M, et al., Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med, 2001. 344(22): p. 1651–8. [PubMed] [Google Scholar]

67. Poole-Wilson PA, et al., Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet, 2003. 362(9377): p. 7–13. [PubMed] [Google Scholar]

68. Granger CB, et al., Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet, 2003. 362(9386): p. 772–6. [PubMed] [Google Scholar]

69. Zannad F, et al., Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med, 2011. 364(1): p. 11–21. [PubMed] [Google Scholar]

70. Yancy CW, et al., 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Card Fail, 2017. [PubMed] [Google Scholar]

Page 2

Baseline therapy in heart failure clinical trials